Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23407545 | 0.86 | HDAC1 (0.70) | HDAC1HDAC6HDAC8HDAC5MLYCD | |
| SCHEMBL19745443 | 0.84 | HDAC1 (0.65) | HDAC1HDAC6HDAC8HDAC5MLYCD | |
| SCHEMBL19745444 | 0.84 | HDAC1 (0.65) | HDAC1HDAC6HDAC8HDAC5MLYCD | |
| SCHEMBL22217910 | 0.83 | HDAC6 (0.67) | HDAC1HDAC6HDAC8HDAC5MLYCD | |
| SCHEMBL16211548 | 0.83 | HDAC6 (0.67) | HDAC1HDAC6HDAC8HDAC5MLYCD | |
| SCHEMBL30493918 | 0.83 | HDAC6 (0.67) | HDAC1HDAC6HDAC8HDAC5MLYCD | |
| SCHEMBL16211302 | 0.83 | HDAC1 (0.66) | HDAC1HDAC6HDAC8HDAC5MLYCD | |
| SCHEMBL22217622 | 0.82 | HDAC1 (0.73) | HDAC1HDAC6HDAC8HDAC5 | |
| SCHEMBL19745672 | 0.82 | MEN1 (0.51) | HDAC1HDAC6HDAC8HDAC5 | |
| SCHEMBL6843873 | 0.81 | MLYCD (0.66) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475275-B1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3475275-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017222951-A1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC8 11/4885 |
| US-20190185462-A1 | 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.